R&D Cardiologie
16
2
3
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
6.3%
1 terminated/withdrawn out of 16 trials
90.0%
+3.5% vs industry average
44%
7 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Evaluation of Ablation Lesions Using Cardiovascular Magnetic Resonance Imaging
Role: lead
Deliver mOre aPplications for More Durable Pulmonary Vein IsOlation
Role: lead
Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulation Therapy
Role: lead
Platelet-activation and Optimal Inhibition in Patients With Atrial Fibrillation Undergoing Left Atrial Appendage Occlusion
Role: lead
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
Role: lead
Evaluation and Comparison of Several Point-of-care Platelet Function Tests in Predicting Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI.
Role: lead
Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
Role: lead
Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contractile Force, and Clinical Performance in Patients With Ventricular Dysfunction and Heart Failure
Role: lead
A Comparison of the TIMI, GRACE and HEART Scores
Role: lead
Sirolimus-eluting vs Zotarolimus-eluting Stents for Chronic Total Coronary Occlusions
Role: lead
Changes in Myocardial Perfusion During Chronic Multi Site Biventricular Versus Right Ventricular Apex Pacing in Patients With Normal Left Ventricular Function Undergoing His Bundle Ablation for Drug-refractory Atrial Fibrillation
Role: lead
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
Role: lead
Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During and After Carotid Artery Stenting (CAS) in Asymptomatic Patients Prior to Cardiac Surgery
Role: lead
Myocardial Infarction Size Reduction With Atorvastatin
Role: lead
Sirolimus-Eluting Stents for Chronic Total Coronary Occlusions
Role: lead
Thrombectomy and Improvement of Left Ventricular Function in AMI
Role: lead
All 16 trials loaded